Heribert Hänscheid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Heribert Hänscheid has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Christoph Reiners
3 shared publications- Michael Lassmann
Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
3 shared publications Markus Luster
2 shared publicationsRichard T Kloos
Department of Nuclear Medicine, University of Würzburg, Oberdürrbacher Straße 6, D-97080 Würzburg, Germany1Divisions of Endocrinology and Nuclear Medicine, Departments of Internal Medicine and Radiology, The Ohio State University, 446 McCampbell Hall, 1581 Dodd Drive Columbus, OH 43210-1296, USA
2 shared publicationsAl Driedger
1 shared publication- Andreas Konrad Buck
Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany
1 shared publication
Latest Publications
- 1 December 2011
- Published by Elsevier in Zeitschrift für Medizinische Physik
- Vol. 21 (4) , 250-257
Dosimetry prior to I-131-therapy of benign thyroid disease
- 1 December 2011
- Published by Elsevier in Zeitschrift für Medizinische Physik
- Vol. 21 (4) , 250-257
Dosimetry prior to I-131-therapy of benign thyroid disease
- 1 November 2011
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (11) , 3511-3516
Facing the Nuclear Threat: Thyroid Blocking Revisited
People being exposed to potentially harmful amounts of radioactive iodine need prophylaxis to prevent high radiation-absorbed doses to the thyroid.
- 1 November 2011
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (11) , 3511-3516
Facing the Nuclear Threat: Thyroid Blocking Revisited
People being exposed to potentially harmful amounts of radioactive iodine need prophylaxis to prevent high radiation-absorbed doses to the thyroid.
- Open Access
- 1 December 2009
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 16 (4) , 1283-1289
Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma
A simple method is presented to estimate the radiation-absorbed dose to the blood after radioiodine administration from a single external measurement of the whole-body retention in patients suffering from differentiated thyroid cancer. The blood dose is calculated applying the formalism of the Medical International Radiation Dose Committee under the assumptions that whole-body activity decays exponentially and that 14% of the whole-body residence time can be attributed to the blood. Accuracy and applicability of the method were tested based on data from 29 assessments, 18 pre-therapeutic tracer studies, and 11 ablation therapies, with whole-body and blood-retention measurements over at least 4 days. The mean of the absolute deviations between estimates and actual blood doses was found to be 14%, if external whole-body counting was performed on day 1 or 2 after radioiodine administration. This simple formalism is: 1) applicable to pre-therapeutic dosimetry for remnant ablation or treatment of metastases in a blood dose-based treatment concept and 2) applicable to blood-dose estimates after radioiodine therapy to determine radiation exposure. When combined with a measurement of the whole body retention 1 or 2 days after radioiodine administration this single time-point method closely approximates the classic, yet much more labor intensive multi-day dosimetry that measures both blood and whole-body activities.
- 1 December 2009
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 16 (4) , 1283-1289
Open AccessBlood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma
A simple method is presented to estimate the radiation-absorbed dose to the blood after radioiodine administration from a single external measurement of the whole-body retention in patients suffering from differentiated thyroid cancer. The blood dose is calculated applying the formalism of the Medical International Radiation Dose Committee under the assumptions that whole-body activity decays exponentially and that 14% of the whole-body residence time can be attributed to the blood. Accuracy and applicability of the method were tested based on data from 29 assessments, 18 pre-therapeutic tracer studies, and 11 ablation therapies, with whole-body and blood-retention measurements over at least 4 days. The mean of the absolute deviations between estimates and actual blood doses was found to be 14%, if external whole-body counting was performed on day 1 or 2 after radioiodine administration. This simple formalism is: 1) applicable to pre-therapeutic dosimetry for remnant ablation or treatment of metastases in a blood dose-based treatment concept and 2) applicable to blood-dose estimates after radioiodine therapy to determine radiation exposure. When combined with a measurement of the whole body retention 1 or 2 days after radioiodine administration this single time-point method closely approximates the classic, yet much more labor intensive multi-day dosimetry that measures both blood and whole-body activities.
- 1 April 2006
- Vol. 47 (4) , 648-54
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Technical aspects and results of the dosimetric assessments of postoperative radioiodine ablation in the framework of an international, prospective, controlled, randomized, comparative study of the effectiveness of ablation therapy with 3.7 GBq (131)I in differentiated thyroid cancer after stimulation with recombinant human TSH (rhTSH) or by thyroid hormone withdrawal (THW) are presented. Sixty-three patients were randomized after thyroidectomy to either the THW or the rhTSH group. Scintigraphic neck images were acquired starting 48 h after radioiodine administration to assess biokinetics in the thyroid remnant. The activity in blood samples was quantified and data from whole-body probe measurements and scintigraphic whole-body scans were combined to deduce retention curves in blood and whole body, respectively. The absorbed dose to the blood was calculated using a modified approach based on the formalism of the MIRD Committee of the Society of Nuclear Medicine. The effective half-time in the remnant thyroid tissue was significantly longer after rhTSH than THW (67.6 +/- 48.8 vs. 48.0 +/- 52.6 h, respectively; P = 0.01), whereas the observed differences of the mean 48-h (131)I uptakes (0.5% +/- 0.7% vs. 0.9% +/- 1.0% after THW; P = 0.1) and residence times (0.9 +/- 1.3 vs. 1.4 +/- 1.5 h after THW; P = 0.1) between the rhTSH and THW groups were not statistically significant. The specific absorbed dose to the blood was significantly (P <0.0001) lower after administration of rhTSH (mean, 0.109 +/- 0.028 mGy/MBq; maximum, 0.18 mGy/MBq) than after THW (mean, 0.167 +/- 0.061 mGy/MBq; maximum, 0.35 mGy/MBq), indicating that higher activities of radioiodine might be safely administered after exogenous stimulation with rhTSH. Indication of an influence of the residence time of radioiodine in the blood on the fractional uptake into thyroid remnant was found. A novel regimen is proposed in which therapeutic activities to be administered are determined from the individual specific blood dose.
- 1 April 2006
- Vol. 47 (4) , 648-54
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Technical aspects and results of the dosimetric assessments of postoperative radioiodine ablation in the framework of an international, prospective, controlled, randomized, comparative study of the effectiveness of ablation therapy with 3.7 GBq (131)I in differentiated thyroid cancer after stimulation with recombinant human TSH (rhTSH) or by thyroid hormone withdrawal (THW) are presented. Sixty-three patients were randomized after thyroidectomy to either the THW or the rhTSH group. Scintigraphic neck images were acquired starting 48 h after radioiodine administration to assess biokinetics in the thyroid remnant. The activity in blood samples was quantified and data from whole-body probe measurements and scintigraphic whole-body scans were combined to deduce retention curves in blood and whole body, respectively. The absorbed dose to the blood was calculated using a modified approach based on the formalism of the MIRD Committee of the Society of Nuclear Medicine. The effective half-time in the remnant thyroid tissue was significantly longer after rhTSH than THW (67.6 +/- 48.8 vs. 48.0 +/- 52.6 h, respectively; P = 0.01), whereas the observed differences of the mean 48-h (131)I uptakes (0.5% +/- 0.7% vs. 0.9% +/- 1.0% after THW; P = 0.1) and residence times (0.9 +/- 1.3 vs. 1.4 +/- 1.5 h after THW; P = 0.1) between the rhTSH and THW groups were not statistically significant. The specific absorbed dose to the blood was significantly (P <0.0001) lower after administration of rhTSH (mean, 0.109 +/- 0.028 mGy/MBq; maximum, 0.18 mGy/MBq) than after THW (mean, 0.167 +/- 0.061 mGy/MBq; maximum, 0.35 mGy/MBq), indicating that higher activities of radioiodine might be safely administered after exogenous stimulation with rhTSH. Indication of an influence of the residence time of radioiodine in the blood on the fractional uptake into thyroid remnant was found. A novel regimen is proposed in which therapeutic activities to be administered are determined from the individual specific blood dose.
- 1 January 2003
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 42 (01) , 45-48
Monitoring of 131I incorporation in nuclear medicine personnel by self accomplished measurements
Aim: The personnel in nuclear medicine therapy wards must be monitored according to German guidelines for incorporations of 131I. A surveillance with the employees measuring themselves similarly to the autonomous contamination survey using hand-foot-clothing monitors is presented as an alternative to the monitoring according to the official guidelines. Method: The employees use a dedicated device to measure themselves every working day. The automatic individual positioning of the device ensures reliable and reproducible results. The thyroid dose is determined from the measured time activity curve. The individual values of depth and mass of the thyroid are taken into account for activity measurement and dose evaluation, respectively. Results: The employees measure themselves regularly and utilize the device to check for activities in the thyroid at an early stage after suspected incorporation. The almost complete surveillance permits a dosimetry with slight uncertainty. The determined thyroid doses of all monitored persons average to 0.35 mSv per month. Conclusion: The incorporation surveillance by autonomous monitoring allows a more reliable and more precise dosimetry than the monitoring according to the official guidelines. Despite numerous measurements the practice saves time and money as a result of the automation. Ziel: Das Personal nuklearmedizinischer Therapiestationen muss nach der Richtlinie für die Physikalische Strahlenschutzkontrolle zur Ermittlung der Körperdosen auf Inkorporation von 131I überwacht werden. Eine zur Richtlinie alternative Überwachung durch Eigenmessung des Personals ähnlich der mit Hand-Fuß-Kleidermonitoren durchgeführten Eigenüberwachung auf Kontamination wird vorgestellt. Methode: Die Mitarbeiter führen die Messungen an einem dedizierten Messplatz täglich eigenständig durch. Die automatische individuelle Positionierung des Messstands garantiert reproduzierbare Messergebnisse. Die Schilddrüsendosis wird aus der gemessenen Zeit/Aktivitätskurve berechnet. Tiefe und Masse der Schilddrüse werden bei der Aktivitätsmessung bzw. Dosisberechnung individuell berücksichtigt. Ergebnisse: Die Mitarbeiter führen die Messungen selbstständig und regelmäßig durch und nutzen das System auch zu Verdachtsmessungen zur frühzeitigen Erkennung von Inkorporationen. Die fast lückenlose Überwachung ermöglicht eine Dosimetrie mit nur geringen Unsicherheiten. Im Mittel liegt die festgestellte Schilddrüsendosis der Mitarbeiter bei etwa 0,35 mSv pro Monat. Schlussfolgerung: Die Inkorporationsüberwachung des Personals durch arbeitstägliche Eigenmessung erlaubt eine genauere Dosimetrie als die Überwachung nach Richtlinie. Trotz vieler Messungen werden durch die Automatisierung Arbeitszeit und Kosten gespart. * Diese Arbeit ist Prof. Dr. Dr. h.c. Heinz Hundeshagen zum 75. Geburtstag gewidmet.
- 1 January 2003
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 42 (01) , 45-48
Monitoring of 131I incorporation in nuclear medicine personnel by self accomplished measurements
Aim: The personnel in nuclear medicine therapy wards must be monitored according to German guidelines for incorporations of 131I. A surveillance with the employees measuring themselves similarly to the autonomous contamination survey using hand-foot-clothing monitors is presented as an alternative to the monitoring according to the official guidelines. Method: The employees use a dedicated device to measure themselves every working day. The automatic individual positioning of the device ensures reliable and reproducible results. The thyroid dose is determined from the measured time activity curve. The individual values of depth and mass of the thyroid are taken into account for activity measurement and dose evaluation, respectively. Results: The employees measure themselves regularly and utilize the device to check for activities in the thyroid at an early stage after suspected incorporation. The almost complete surveillance permits a dosimetry with slight uncertainty. The determined thyroid doses of all monitored persons average to 0.35 mSv per month. Conclusion: The incorporation surveillance by autonomous monitoring allows a more reliable and more precise dosimetry than the monitoring according to the official guidelines. Despite numerous measurements the practice saves time and money as a result of the automation. Ziel: Das Personal nuklearmedizinischer Therapiestationen muss nach der Richtlinie für die Physikalische Strahlenschutzkontrolle zur Ermittlung der Körperdosen auf Inkorporation von 131I überwacht werden. Eine zur Richtlinie alternative Überwachung durch Eigenmessung des Personals ähnlich der mit Hand-Fuß-Kleidermonitoren durchgeführten Eigenüberwachung auf Kontamination wird vorgestellt. Methode: Die Mitarbeiter führen die Messungen an einem dedizierten Messplatz täglich eigenständig durch. Die automatische individuelle Positionierung des Messstands garantiert reproduzierbare Messergebnisse. Die Schilddrüsendosis wird aus der gemessenen Zeit/Aktivitätskurve berechnet. Tiefe und Masse der Schilddrüse werden bei der Aktivitätsmessung bzw. Dosisberechnung individuell berücksichtigt. Ergebnisse: Die Mitarbeiter führen die Messungen selbstständig und regelmäßig durch und nutzen das System auch zu Verdachtsmessungen zur frühzeitigen Erkennung von Inkorporationen. Die fast lückenlose Überwachung ermöglicht eine Dosimetrie mit nur geringen Unsicherheiten. Im Mittel liegt die festgestellte Schilddrüsendosis der Mitarbeiter bei etwa 0,35 mSv pro Monat. Schlussfolgerung: Die Inkorporationsüberwachung des Personals durch arbeitstägliche Eigenmessung erlaubt eine genauere Dosimetrie als die Überwachung nach Richtlinie. Trotz vieler Messungen werden durch die Automatisierung Arbeitszeit und Kosten gespart. * Diese Arbeit ist Prof. Dr. Dr. h.c. Heinz Hundeshagen zum 75. Geburtstag gewidmet.